Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives Posted on June 20, 2024June 20, 2024 by Brady Anna
Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs Posted on September 8, 2023September 11, 2023 by Brady Anna
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology Posted on August 29, 2023 by Brady Anna
First clinical scan using XENOVIEW™ conducted at Cincinnati Children’s Hospital Medical Center Posted on May 11, 2023 by Brady Anna
Polarean to be a featured company at 2023 ATS Respiratory Innovation Summit Posted on May 3, 2023 by Brady Anna
FDA Grants New Chemical Entity designation for XENOVIEW™ (xenon Xe 129 hyperpolarized) Posted on February 14, 2023February 16, 2023 by Brady Anna
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) Posted on December 28, 2022January 26, 2023 by Brady Anna
